gramicidin; neomycin sulfate; polymyxin b sulfate: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bausch And Lomb	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	gramicidin; neomycin sulfate; polymyxin b sulfate	SOLUTION/DROPS;OPHTHALMIC	064047	ANDA	Bausch & Lomb Incorporated	24208-790-62	1 BOTTLE, DROPPER in 1 CARTON (24208-790-62) / 10 mL in 1 BOTTLE, DROPPER	1996-01-31
Bausch And Lomb	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	gramicidin; neomycin sulfate; polymyxin b sulfate	SOLUTION/DROPS;OPHTHALMIC	064047	ANDA	A-S Medication Solutions	50090-0247-0	1 BOTTLE, DROPPER in 1 CARTON (50090-0247-0) / 10 mL in 1 BOTTLE, DROPPER	1996-01-31
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 30, 2025

Introduction

The global pharmaceutical supply chain relies heavily on specialized manufacturers capable of producing antibiotics like Gramicidin, Neomycin Sulfate, and Polymyxin B Sulfate. These agents are critical in combating multi-drug resistant infections, maintaining clinical relevance in various therapeutic areas, including ophthalmology, dermatology, and systemic infections. Identifying reliable suppliers is essential for pharmaceutical companies, healthcare providers, and research institutions to ensure drug availability, quality, and compliance with regulatory standards.

Overview of the Drugs

Gramicidin is a peptide antibiotic primarily used in topical formulations for skin infections. Its production is complex due to its peptide nature, necessitating specialized microbial fermentation processes.

Neomycin Sulfate belongs to the aminoglycoside class of antibiotics, widely employed in topical, ophthalmic, and systemic formulations. Its manufacturing involves large-scale fermentation of Streptomyces fradiae.

Polymyxin B Sulfate is a cationic polypeptide antibiotic used mainly against Gram-negative bacteria. It is produced through fermentation of Bacillus polymyxa, requiring stringent purification processes.

Global Landscape of Suppliers

1. Established Manufacturers and Bulk Suppliers

a. Swiss-based Bachem Group

The Bachem Group, a leader in peptide synthesis and high-quality APIs, supplies Gramicidin, leveraging advanced fermentation and synthesis technologies. Their expertise ensures compliance with Good Manufacturing Practices (GMP) and consistent product quality suitable for pharmaceutical formulations ([1]).

b. Canadian and Indian Manufacturers of Neomycin Sulfate

Canada's reputable companies such as Neobiotech, and Indian firms including Zydus Cadila and Ipca Laboratories, produce Neomycin Sulfate at large scale. These companies employ optimized fermentation protocols for high-yield, bioequivalent APIs ([2], [3]).

c. European and Chinese Manufacturers of Polymyxin B

Prominent producers of Polymyxin B include Chinese companies such as Qilu Pharmaceutical and North China Pharmaceutical Group Corporation, and established European players like EuroPharma, which focus on advanced fermentation processes and stringent purification to meet international standards ([4], [5]).

2. Emerging and Contract Manufacturing Organizations (CMOs)

Many pharmaceutical firms depend on CMOs for these antibiotics. Notable CMOs include:

Fujifilm Diosynth Biotechnology: Offers contract manufacturing for peptide antibiotics, including Gramicidin, utilizing cutting-edge fermentation and purification tech ([6]).
Lonza: Supplies antibiotics like Neomycin and specialized peptides through scalable GMP facilities, catering to both clinical and commercial needs ([7]).
BASF: Engages in the production of Polymyxin B compounds, focusing on scalable synthesis complemented by rigorous quality controls ([8]).

3. Regional Suppliers and Market Dynamics

The Asia-Pacific region, especially China and India, dominates global production due to cost advantages and substantial capacity. However, demand for high-purity APIs with strict regulatory compliance has driven the expansion of European and North American suppliers into high-quality markets.

Criteria for Selecting Suppliers

When sourcing Gramicidin, Neomycin Sulfate, or Polymyxin B Sulfate, consider:

Regulatory Compliance: Suppliers must adhere to GMP, ISO certifications, and pharmacopoeial standards (USP, EP, BP).
Quality Assurance: Consistent API purity (>95%), low endotoxin levels, and detailed analytical documentation.
Capacity and Reliability: Ability to meet demand forecasts with scalable production lines.
Traceability and Documentation: Comprehensive batch records, stability data, and clear supply chain documentation.
Pricing and Lead Time: Competitive costs without compromising integrity, with reliable logistics and delivery timelines.

Emerging Trends and Challenges

Supply Chain Security: The reliance on regional producers raises concerns amid geopolitical tensions and trade restrictions. Diversification of supply sources and strategic inventory management are imperative.

Regulatory Harmonization: Variability in regional standards necessitates comprehensive validation procedures for API suppliers, especially when importing from emerging markets.

Technological Advances: Innovations in microbial fermentation and peptide synthesis are enabling higher yields, improved purity, and reduced manufacturing costs, broadening supplier options.

Environmental and Sustainability Standards: Growing emphasis on eco-friendly manufacturing processes influences supplier selection, favoring companies with sustainable practices.

Conclusion

The procurement landscape for Gramicidin, Neomycin Sulfate, and Polymyxin B Sulfate features a diverse array of suppliers spanning continents and capabilities. Reputable companies in Europe, North America, and Asia serve as primary providers, with a robust network of CMOs supplementing in-house manufacturing. Ensuring supply chain resilience requires meticulous supplier vetting aligned with regulatory, quality, and operational standards.

Key Takeaways

Diversify Suppliers: Engaging multiple qualified providers mitigates risks associated with regional disruptions or regulatory changes.
Prioritize Quality & Compliance: Regulatory adherence and consistent API purity are non-negotiable for pharmaceutical applications.
Leverage Strategic Partnerships: Collaborate with established CMOs and manufacturers with advanced fermentation and synthesis technology.
Stay Ahead of Market Trends: Monitor technological innovations and environmental practices influencing supplier capabilities.
Plan for Supply Chain Resilience: Incorporate contingency strategies such as increased inventory or alternative sourcing options.

Frequently Asked Questions (FAQs)

Q1: Are there any synthetic alternatives to naturally fermented antibiotics like Neomycin and Polymyxin B?
Yes. Advances in peptide synthesis and chemical modification have led to synthetic analogs; however, most APIs like Neomycin and Polymyxin B are predominantly produced via fermentation due to cost-effectiveness and efficacy.

Q2: How can I verify a supplier’s compliance with regulatory standards?
Request detailed documentation including GMP certification, audits, analytical data, and lot-specific certificates of analysis (COA). Confirm adherence to pharmacopeial standards relevant to your jurisdiction.

Q3: Which regions offer the most reliable suppliers for these antibiotics?
Europe and North America maintain high regulatory standards for pharmaceutical APIs. Asia, especially China and India, offer large-scale manufacturing with robust quality controls, though due diligence is essential.

Q4: Are there any new entrants in the market for these antibiotics?
Emerging biotech firms and CMOs are investing in novel fermentation techniques and synthesis methods, but market dominance remains with established players.

Q5: What are the main challenges in sourcing these antibiotics?
Challenges include regulatory hurdles, supply chain disruptions, ensuring consistent quality, and dealing with geopolitical trade issues.

References

Bachem Group. (2022). Advanced Peptide and API Manufacturing.
Neobiotech. (2023). Neomycin Sulfate Production Capabilities.
Zydus Cadila. (2022). API Manufacturing for Aminoglycosides.
Qilu Pharmaceutical. (2023). Polymyxin B Production Overview.
EuroPharma. (2022). European Polymyxin B Supply Chain.
Fujifilm Diosynth Biotechnology. (2023). Contract Manufacturing Services.
Lonza Group. (2023). API Manufacturing of Aminoglycosides.
BASF. (2022). Polymyxin B Production and Quality Assurance.

This comprehensive overview aims to assist stakeholders in making informed procurement decisions for these critical antibiotics by highlighting leading suppliers, recent trends, and essential considerations.

Suppliers and packagers for generic pharmaceutical drug: gramicidin; neomycin sulfate; polymyxin b sulfate